arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Insight Molecular Diagnostics Inc.

IMDX
$4.85 ▼ -0.17 (-3.39%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
13 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
55
Health
Fair
Bullish
auto_awesome

Analytical Summary

Insight Molecular Diagnostics Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $147.8M
Dividend Yield
Revenue Growth 115.6%
Op. Margin
ROIC 128.4%
FCF / Share $-0.83
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.05M
↑ +115.6%
Net Income Profit after all expenses
$-50.22M
↑ +17.2%
FCF / Share Free cash flow per share
$-0.83
↑ +48.7%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health
6
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters